Eccentric calcification was found to be associated with longitudinal transcatheter heart valve distortion.
Use of the PASCAL system during transcatheter valve repair for symptomatic tricuspid regurgitation was found to be safe and effective at 30 days.
Rates of acute kidney injury were found to be higher in patients with severe symptomatic aortic stenosis undergoing TAVI who had more advanced extravalvular cardiac damage.
Patients with bicuspid aortic valve stenosis and BMI at increased risk for high residual gradient following TAVR.
The continuation of oral anticoagulation during TAVR did not increase bleeding or vascular complication rates.
Invasive assessment of cardiopulmonary hemodynamics may predict survival after transcatheter tricuspid edge-to-edge valve repair in patients with severe tricuspid regurgitation and symptomatic heart failure.
In 2019, TAVR exceeded surgical procedures; 30-day mortality and stroke rates decreased since 2011.
The Emory risk score was found to have modest value for predicting permanent pacemaker implantation.
Patients who have truncus arteriosus with moderate or worse initial truncal valve regurgitation or stenosis may be at risk for truncal valve intervention.
Coronary cannulation failures following transcatheter aortic valve replacement were found to be higher in patients receiving Evolut TAVs.